• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Bicycle Therapeutics plc

    8/14/25 8:57:36 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCYC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    BICYCLE THERAPEUTICS PLC

    (Name of Issuer)


    American Depositary Shares, each representing one ordinary share, nominal value 0.01 per share

    (Title of Class of Securities)


    09060C507

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09060C507


    1Names of Reporting Persons

    Armistice Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    359,703.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    359,703.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    359,703.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    09060C507


    1Names of Reporting Persons

    Steven Boyd
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    359,703.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    359,703.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    359,703.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.99 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BICYCLE THERAPEUTICS PLC
    (b)Address of issuer's principal executive offices:

    BLOCKS A & B, PORTWAY BUILDING, GRANTA PARK, GREAT ABINGTON, CAMBRIDGE, United Kingdom, CB21 6GS
    Item 2. 
    (a)Name of person filing:

    Armistice Capital, LLC Steven Boyd Collectively, the "Reporting Persons"
    (b)Address or principal business office or, if none, residence:

    Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America Steven Boyd c/o Armistice Capital, LLC 510 Madison Avenue, 7th Floor New York, New York 10022 United States of America
    (c)Citizenship:

    Armistice Capital, LLC - Delaware; Steven Boyd - United States of America
    (d)Title of class of securities:

    American Depositary Shares, each representing one ordinary share, nominal value 0.01 per share
    (e)CUSIP No.:

    09060C507
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    359,703
    (b)Percent of class:

    4.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    359,703

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    359,703 The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer. Armistice Capital, LLC ("Armistice Capital") is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Armistice Capital, LLC
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd - Managing Member
    Date:08/14/2025
     
    Steven Boyd
     
    Signature:/s/ Steven Boyd
    Name/Title:Steven Boyd
    Date:08/14/2025
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: August 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

    Get the next $BCYC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCYC

    DatePrice TargetRatingAnalyst
    11/8/2024$25.00Equal-Weight
    Stephens
    9/6/2024$35.00Outperform
    RBC Capital Mkts
    8/7/2024$33.00 → $28.00Buy → Neutral
    B. Riley Securities
    9/11/2023Neutral → Buy
    B. Riley Securities
    8/31/2022Outperform
    Cowen
    7/28/2022$30.00Overweight
    Barclays
    7/6/2022$60.00Buy
    Canaccord Genuity
    4/13/2022$62.00 → $33.00Buy → Neutral
    B. Riley Securities
    More analyst ratings

    $BCYC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

    Continued advancement across research and development pipeline, with key program updates expected in 2H 2025 Phase 1/2 Duravelo-4 trial for zelenectide pevedotin in NECTIN4-amplified non-small cell lung cancer open and actively recruiting patients Strengthened clinical leadership and bolstered roster of scientific advisors with additions to Board of Directors and creation of Research and Innovation Advisory Board Strategic cost realignment of approximately 30%, primarily through a workforce reduction Cash and cash equivalents of $721.5 million as of June 30, 2025, with expected financial runway extended into 2028 Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pio

    8/8/25 7:00:00 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on July 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 77,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price equal to $6.95 per share, Bicycle Therapeutics' closing trading price on June 30, 2025, and will vest over four years, with 25%

    7/2/25 4:05:00 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Bicycle Therapeutics with a new price target

    Stephens initiated coverage of Bicycle Therapeutics with a rating of Equal-Weight and set a new price target of $25.00

    11/8/24 7:35:57 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Bicycle Therapeutics with a new price target

    RBC Capital Mkts initiated coverage of Bicycle Therapeutics with a rating of Outperform and set a new price target of $35.00

    9/6/24 7:31:26 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics downgraded by B. Riley Securities with a new price target

    B. Riley Securities downgraded Bicycle Therapeutics from Buy to Neutral and set a new price target of $28.00 from $33.00 previously

    8/7/24 6:40:33 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baker Bros. Advisors Lp bought $21,230,385 worth of American Depositary Shares (1,485,397 units at $14.29) (SEC Form 4)

    4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

    12/17/24 6:03:39 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    SEC Filings

    View All

    SEC Form EFFECT filed by Bicycle Therapeutics plc

    EFFECT - BICYCLE THERAPEUTICS PLC (0001761612) (Filer)

    8/15/25 12:15:26 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Bicycle Therapeutics plc

    SCHEDULE 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    8/14/25 8:57:36 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Bicycle Therapeutics plc

    SCHEDULE 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    8/14/25 4:45:36 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Swanton Robert Charles was granted 12,500 units of Ordinary Shares, increasing direct ownership by 405% to 15,589 units (SEC Form 4)

    4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

    8/14/25 4:26:11 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Swanton Robert Charles claimed ownership of 3,089 units of Ordinary Shares (SEC Form 3)

    3 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

    8/14/25 4:23:55 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Lee Kevin sold $39,836 worth of Ordinary Shares (5,461 units at $7.29), decreasing direct ownership by 1% to 480,804 units (SEC Form 4)

    4 - BICYCLE THERAPEUTICS PLC (0001761612) (Issuer)

    7/7/25 5:20:14 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Leadership Updates

    Live Leadership Updates

    View All

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

    Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer; Duravelo-2 dose selection data expected in 2H 2025 Enhanced response to zelenectide pevedotin seen in NECTIN4 gene-amplified late-line breast cancer and non-small cell lung cancer (NSCLC), resulting in U.S. FDA Fast Track designations for triple-negative breast cancer and NSCLC; several Phase 1/2 trials expected to start in 2025 Advancing radiopharmaceuticals pipeline, with additional MT1-MMP human imaging data expected in mid-2025 and first EphA2 human imaging data planned for

    2/25/25 7:00:00 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

    Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the company's clinical oncology programs. "We are delighted to welcome Skip, Markus and Niklas to our Clinical Advisory Board. Each of them has dedicated their careers to advancing the care of patients with cancer through the development of novel therapeutics," said Bicycle Therapeutics CEO Kevin Lee, Ph.D. "Their expertise will provide invaluable guidance

    12/10/24 7:00:00 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Financials

    Live finance-specific insights

    View All

    Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

    Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025 Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated an enhanced response to zelenectide pevedotin Company to advance development strategy leveraging NECTIN4 gene amplification, with Phase 1/2 trials in breast cancer, lung cancer and multi-tumor planned for 2025 Bicycle Therapeutics to host conference call and webcast with management and

    12/12/24 6:30:00 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

    Abstract outlines data showing enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer patients with NECTIN4 gene amplification Company to announce topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer Conference call and webcast scheduled for Friday, Dec. 13, at 7 a.m. CT to review all data Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the

    11/25/24 5:30:00 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

    First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use Additional preclinical data demonstrate biodistribution of BRCs can be optimized to maintain high tumor uptake while significantly reducing kidney levels Company strategy focuses on pursuing novel targets using a range of isotopes to develop radiopharmaceuticals with first-in-class potential Bicycle Therapeutics to host conference call and webcast today at 8 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therap

    10/23/24 7:00:00 AM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCYC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Bicycle Therapeutics plc

    SC 13D/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    12/17/24 6:46:27 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

    SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    11/14/24 5:46:12 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bicycle Therapeutics plc

    SC 13G/A - BICYCLE THERAPEUTICS PLC (0001761612) (Subject)

    11/14/24 4:32:50 PM ET
    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care